Loading
Radiotherapy / Oligoprogressive / Radiofrequent ablation · Phase 2 Trial
ClinicalTrials.gov · September 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 trial registration for the COSMO study, which is actively recruiting to evaluate local ablative therapy (SABR, surgery, or percutaneous ablation) in patients with oligoprogressive metastatic breast cancer during palliative systemic therapy. No results are reported in this registry record; the primary endpoint is progression-free status at 6 months.
Phase 2, Interventional, Single Group, Open label, Treatment purpose. Breast Cancer Invasive, Metastatic Cancer, Oligoprogressive; age from 18 Years. Intervention: Surgery, radiotherapy or radiofrequent ablation. n = 56. 7 sites: Netherlands.
This is a Phase 2 trial registration for the COSMO study, which is actively recruiting to evaluate local ablative therapy (SABR, surgery, or percutaneous ablation) in patients with oligoprogressive metastatic breast cancer during palliative systemic therapy. No results are reported in this registry record; the primary endpoint is progression-free status at 6 months.
This is a registry record only; no efficacy, safety, or outcome data are reported.
The source did not state who this applies to in practice.
This is an active Phase 2 interventional trial with no results reported; the registry record describes planned enrollment and endpoints only, not outcomes.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05301881). This is a study registration, not published results. Lead sponsor: The Netherlands Cancer Institute. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 56 participants (ESTIMATED). Conditions: Breast Cancer Invasive, Metastatic Cancer, Oligoprogressive. Interventions: PROCEDURE: Surgery; RADIATION: Radiotherapy; OTHER: Radiofrequent ablation. Primary outcome measures: Number of patients free of progression at 6 months , At 6 months. Brief summary: Patients with oligoprogression of metastatic breast cancer during palliative treatment that is amenable to local therapy will be included. The local ablative therapy (LAT) may consist of stereotactic ablative radiotherapy (SABR), also known as stereotactic body radiation therapy, surgery or percutaneous ablation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.